Sarepta Therapeutics disclosed that its Phase 3 EMBARK study of the gene therapy ELEVIDYS achieved statistically significant, clinically meaningful benefits at the three‑year mark for ambulatory Duchenne muscular dystrophy patients. The study, which enrolled 52 treated patients and 73 external controls, showed a 73 % slowing of disease progression on the Time to Rise (TTR) test and a 70 % improvement on the 10‑meter walk/run (10MWR), with treated patients maintaining mean North Star Ambulatory Assessment (NSAA) scores above baseline.
The three‑year data reinforce the long‑term efficacy profile that has underpinned the company’s sales momentum. A 73 % reduction in the rate of decline on TTR and a 70 % reduction on 10MWR translate into a sustained functional advantage that is expected to strengthen physician and payer confidence, thereby supporting continued market penetration and pricing stability for ELEVIDYS.
Sarepta’s commercial performance reflected the clinical gains. Net product revenue for the fourth quarter of 2025 reached $110.4 million, a decline from $384.2 million in Q4 2024, largely due to a severe year‑end flu season that forced the rescheduling of patient infusions into 2026. Full‑year 2025 revenue climbed to $898.7 million, up 9.5 % from $820.8 million in 2024, driven by robust demand in the U.S. market and expanding access in international territories.
Management emphasized the significance of the results. Louise Rodino‑Klapac, Ph.D., president of research & development, said the data “demonstrate a dramatic shift in disease trajectory out to three years, consistent with earlier long‑term data extending up to five years.” CEO Doug Ingram noted that the company’s performance “substantially exceeded prior guidance” and that the positive data will help sustain the company’s growth trajectory despite the Q4 revenue dip.
Analysts reacted positively to the sustained efficacy and the absence of new safety signals, which mitigated concerns about the boxed warning for acute liver injury. The market’s favorable response was driven by the strong functional outcomes and the company’s ability to maintain revenue growth in the face of short‑term headwinds. The data also reinforce the company’s competitive advantage as the only approved gene therapy for Duchenne, positioning it well against emerging competitors.
Sarepta’s collaboration with Roche for global commercialization and the ongoing expansion of its reimbursement strategy are expected to further support sales. The company’s focus on operational efficiency and patient access initiatives signals confidence in sustaining long‑term growth while managing the risks associated with rare‑disease therapeutics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.